You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Cobalt™ ICDs and CRT-Ds are enabled with BlueSync™ technology, allowing for tablet-based programming and app-based remote monitoring, and offer exclusive algorithms to manage atrial fibrillation (AF) patients.
Additional ResourcesMeet Cobalt ICDs and CRT-Ds
With exclusive algorithms to manage AF, heart failure risk stratification (CRT-D), tablet-based programming and app-based remote monitoring, extended longevity, and 40 J on all shocks.
Real-world projections based on CareLink™ patient data.
MAXIMUM
DELIVERED
ENERGY<sup>†</sup>
40 J
MAXIMUM
STORED
ENERGY<sup>‡</sup>
47 J
Single Chamber
Dual Chamber and CRT-D
AF Episode Detection Accuracy (PPV)<sup>§||10</sup>
Dual Chamber and CRT-D
BlueSync technology within Cobalt enables secure, wireless communication.
Tablet-based CareLink SmartSync™ device manager
Cobalt ICDs and CRT-Ds
MyCareLink Heart™ mobile app or MyCareLink Relay™ Home Communicator
CareLink network and the BeConnected service
TriageHF™ in Cobalt CRT-D is a simplified, integrated heart failure risk assessment tool that alerts clinicians to clinically relevant changes in a patient’s status that may lead to a heart failure decompensation.
Patient’s risk level is
generated by assessing15:
Risk score
Risk of a HF hospitalisation in the next 30 days16
HIGHHazard Ratio 10x
MEDIUMHazard Ratio 2.1x
LOWNeg Pred Value 99.4%
Discover exclusive features and algorithms available in Cobalt ICDs and CRT-Ds.
Find additional feature information along with a variety of educational resources and tools.
Visit Medtronic AcademyWith AdaptivCRT™ programmed to BiV and LV.
Energy delivered at connector block into a 50 Ω ± 1% load.
Energy stored at charge end on capacitor.
A controlled, head-to-head study evaluating the comparative performance of device algorithms has not been done. AF detection accuracy rates determined from independent clinical trials are presented for reference.
Detection accuracy is compared using PPV, which is the percentage of all AT/AF episodes detected by the individual device detection algorithm that were adjudicated as true AT/AF.
Compared to matched control group.
Most of the reduction in AF occurred in subgroups with prolonged AV conduction at baseline and with significant left atrial reverse remodeling.
Medtronic Claria MRI™ Quad CRT-D SureScan™ and Amplia MRI™ Quad CRT-D SureScan™ Median Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.
Medtronic Cobalt™ HF Quad CRT-D MRI SureScan™ Model DTPB2QQ device manual (example).
Medtronic Evera MRI™ XT DR SureScan™ and Evera MRI™ S DR SureScan™ Median Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.
Medtronic Cobalt™ DR MRI SureScan™ Model DDPB3D4 device manual (example).
Medtronic Visia AF™ VR and Visia AF MRI™ VR SureScan™ Median Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.
Medtronic Cobalt™ VR ICD MRI SureScan™ Model DVPB3D4 device manual (example).
Sprenger M. Comparison of Manufacturer’s AT/AF Detection Accuracy across Clinical Studies. January 2015. Medtronic data on file.
Pürerfellner H, Gillis AM, Holbrook, Hettrick DA. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol. July 2004;27(7):983-992.
Ziegler PD, et al. Accuracy of Atrial Fibrillation Detection in Implantable Pacemakers. Presented at HRS 2013 (PO02-08); Denver, CO.
Medtronic data on file. QADoc DSN026170, Version 2.0, “AT/AF Duration Performance Comparison.”
Kauffman ES, Israel CW, Nair GM, et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm. August 2012;9(8):1241-1246.
Nowak B, McMeekin J, Knops M, et al. Validation of dual-chamber pacemaker diagnostic data using dual-channel stored electrograms. Pacing Clin Electrophysiol. July 2005;28(7):620-629.
Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. Pacing Clin Electrophysiol. July 2019;42(7):970-979.
Birnie D, Hudnall H, Lemke B, et al. Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients: Results of the Adaptive Cardiac Resynchronization Therapy Trial. Heart Rhythm. December 2017;14(12):1820-1825.
Medtronic CareLink™ Heart Failure Risk Status Technical Manual M945636A001 A.
Cowie MR, Sarkar S, Koehler J, et al. Development and validation of an integrated diagnostic algorithm derived from parameters monitored in implantable devices for identifying patients at risk for heart failure hospitalization in an ambulatory setting. Eur Heart J. August 2013;34(31):2472-2480.